Novo Nordisk stock sinks after 2030 growth plan fails to impress investors
The Danish drugmaker pledged to launch 5 multi-blockbuster drugs by 2030 and grow revenue in line with peers, but investors wanted more
We haven't written up this one. Quartz has the full story — the link below goes straight to it.